Requip
Formulated to manage restless legs syndrome to support sleep quality.
Strengths: 0.25 · 0.5 · 1 · 2mg
Where to Check Availability
Medicine details
- Alternative names
Requip XL
- Therapeutic class
Dopamine Receptor Agonist
- Pharmacological class
Dopamine Agonist
- Minor side effects
nausea; dizziness; somnolence; fatigue
- Moderate side effects
hallucinations; confusional state; peripheral oedema; dyspepsia
- Dosage forms
Film-coated tablet; Prolonged-release tablet
- Administration route
Oral use
- Patient summary
Formulated to manage restless legs syndrome to support sleep quality.
- Prescription status
POM
- Manufacturer
GSK
- Onset Time
1–2 hours
- Duration
Modified release formulations allow 24-hour effect
- Storage instructions
Store at room temperature.
- Drug interactions
antipsychotics; hormone replacement therapy
- Age restrictions
Not indicated for children.
Contraindications
severe renal impairment; severe hepatic impairment; hypersensitivity to ropinirole
Precautions and warnings
monitor for impulsive behaviour; avoid abrupt cessation; may cause sudden onset of sleep
Serious side effects
impulse control disorders — requires immediate medical attention; neuroleptic malignant syndrome — requires immediate medical attention
Mechanism of action
Stimulates dopamine receptors in the striatum, which helps to mitigate motor symptoms and involuntary muscle sensations.
Pregnancy and breastfeeding
Pregnancy: Inform your doctor if planning pregnancy. Breastfeeding: Not recommended.
Requip
Formulated to manage restless legs syndrome to support sleep quality.
Editorial Notes
- Active ingredient(s): Ropinirole
- Listed indication(s): Parkinson’s Disease, Restless Legs Syndrome
Usually available as
- 180 tablets - 0.25 mg214-0-25-mg-1417
- 120 tablets - 0.5 mg214-0-5-mg-1410
- 60 tablets - 1 mg214-1-mg-1420